Related Experiment Video
Updated: Jun 18, 2026
05:45
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Heat shock proteins in glioblastomas
Isaac Yang1, Shanna Fang, Andrew T Parsa
1Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Avenue, Room M779, Campus 0112, San Francisco, CA 94143, USA. yangi@neurosurg.ucsf.edu
Neurosurgery Clinics of North America
|December 1, 2009
Summary
Glioblastoma multiforme, a deadly brain cancer, has a poor prognosis. Heat shock protein vaccine therapy shows promise as a novel treatment to improve survival for these patients.
Area of Science:
- Oncology
- Immunology
- Neuro-oncology
Background:
- Glioblastoma multiforme is the most common and aggressive primary central nervous system tumor.
- Current treatment options offer limited efficacy, with a median survival of approximately 14 months and a 5-year survival rate below 2%.
- There is a critical need for novel therapeutic strategies to improve patient outcomes.
Purpose of the Study:
- To explore the potential of heat shock protein (HSP) vaccine therapy as a novel treatment for glioblastoma multiforme.
- To investigate the role of endogenous heat shock proteins in mediating immune responses relevant to cancer treatment.
Main Methods:
- This section is not detailed in the provided abstract.
- Further research is needed to elucidate specific methodologies.
Main Results:
- This section is not detailed in the provided abstract.
- The abstract suggests a rising interest and potential promise for HSP vaccine therapy.
Conclusions:
- Heat shock protein vaccine therapy is emerging as a promising, safe, and multifaceted treatment approach for human cancers.
- This therapy holds potential for improving survival and quality of life in patients with glioblastoma multiforme.
